Company Overview
Esperion Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development and commercialization of medicines specifically designed for patients with elevated low density lipoprotein cholesterol, known as LDL-C, within the United States market. The company functions within the broader Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on specialized therapeutic solutions rather than broad consumer pharmaceuticals. At a significant operational scale, the enterprise employs 294 individuals and maintains a market capitalization of $672.84M, reflecting its valuation in the public equity markets. With reported annual revenue of $403.14M, these financial figures indicate that Esperion has established a substantial commercial footprint, positioning it as a notable player in the specialty drug landscape with sufficient revenue generation to support its R&D and commercialization activities.
Financial Health
The company reported revenue of $403.14M and EBITDA of $60.38M for the trailing twelve months, while posting a net income of -$22,682,000. The substantial gap between the positive EBITDA and the negative net income reveals a cost structure characterized by significant non-operating expenses or interest costs that erode bottom-line profitability despite strong operational earnings. Free cash flow stands at -$52,594,876, indicating that current cash outflows for capital expenditures and working capital exceed operating cash generation, which suggests limited immediate financial flexibility for large-scale acquisitions or aggressive share buybacks. The company maintains a cash reserve of $167.85M against total debt of $548.00M, highlighting a leveraged balance sheet where obligations significantly exceed liquid assets. Debt metrics are further complicated by a debt-to-equity ratio that is not available in current reporting, and a price-to-book ratio of -2.13 which reflects the impact of accumulated losses on book equity. Liquidity is supported by a current ratio of 1.54, indicating that current assets are 1.54 times greater than current liabilities and providing a buffer for short-term obligations. Return on Assets is reported at 9.3%, demonstrating efficient asset utilization relative to total assets, whereas Return on Equity is N/A due to the negative equity position resulting from the company's net losses.
Valuation Assessment
Valuation metrics present a complex picture with a trailing P/E ratio of N/A due to the lack of positive net income, contrasted by a forward P/E of 8.93 which implies market expectations for future earnings recovery or profitability turnaround. The price-to-book ratio is recorded at -2.13, a negative figure that indicates the market is pricing the stock below its adjusted book value, often seen in biotech firms with negative equity but valuable intangible assets or pipeline potential. Alternative valuation measures include a price-to-sales ratio of 1.67 and an EV/EBITDA of 17.44, suggesting that investors are willing to pay a premium relative to sales and earnings before interest, taxes, depreciation, and amortization. The stock's trading range is defined by a 52-week high of $4.18 and a 52-week low of $0.69, providing a historical context for volatility and price discovery. While the current price is not explicitly listed in the provided facts, the forward P/E of 8.93 suggests the market is pricing in significant expected growth to justify the current valuation multiple relative to the low trailing earnings. The beta of 1.11 indicates that the stock's price volatility is 11% higher than the broader market, reflecting the inherent risks and opportunities associated with the biopharmaceutical sector.
Growth & Income
Revenue growth year-over-year is an impressive 143.7%, signaling rapid expansion in sales, while earnings growth year-over-year is N/A due to the company's current unprofitability. The disparity between the robust revenue increase and the absence of earnings growth implies that revenue gains are being consumed by high operating costs or non-recurring charges rather than translating immediately into net profit. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of dividend distribution confirms that the company reinvests all available earnings and cash flows back into research, development, and commercial operations to fuel future growth rather than returning capital to shareholders. The overall growth and income profile is defined by high revenue expansion driven by market adoption of products like NEXLETOL and NEXLIZET, coupled with a strategy of zero dividend payouts to prioritize long-term R&D investment over current income generation.